A share price of Ionis Pharmaceuticals Inc [IONS] is currently trading at $41.55, down -0.46%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IONS shares have lost -1.63% over the last week, with a monthly amount drifted -1.49%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on April 10, 2024, when Wolfe Research upgraded its rating to a Outperform but kept the price target unchanged to $58 for it. Previously, BofA Securities upgraded its rating to Buy on January 02, 2024, and elevated its price target to $62. On October 23, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $52 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $63 on September 29, 2023. Citigroup upgraded its rating to a Buy and raised its price target to $60 on July 31, 2023. In a note dated May 04, 2023, Citigroup upgraded an Neutral rating on this stock and boosted its target price from $30 to $36.
Ionis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $34.32 and $54.44. Currently, Wall Street analysts expect the stock to reach $46.59 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $41.55 at the most recent close of the market. An investor can expect a potential return of 12.13% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Trailing Twelve Months sales for Ionis Pharmaceuticals Inc [NASDAQ:IONS] were 788.14M which represents 113.82% growth. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.45%, Pretax Profit Margin comes in at -0.42%, and Net Profit Margin reading is -0.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.9 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.76.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.19 points at the first support level, and at 40.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.98, and for the 2nd resistance point, it is at 42.41.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ionis Pharmaceuticals Inc [NASDAQ:IONS] is 5.90. Further, the Quick Ratio stands at 5.83, while the Cash Ratio is 0.89. Considering the valuation of this stock, the price to sales ratio is 7.68, the price to book ratio is 15.51.
Transactions by insiders
Recent insider trading involved Monia Brett P, Chief Executive Officer, that happened on Feb 16 ’24 when 387.0 shares were sold. Chief Executive Officer, Monia Brett P completed a deal on Feb 02 ’24 to sell 23501.0 shares. Meanwhile, EVP, Chf GL Pdt Str & Oper Ofc Cadoret-Manier Onaiza sold 2125.0 shares on Feb 02 ’24.
